期刊文献+

不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响 被引量:2

Effect of different dosages of pitavastatin on blood flow recovery in ischemic limbs of mice
下载PDF
导出
摘要 目的探讨不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响,为临床应用合适剂量他汀类药物提供实验依据。方法建立小鼠下肢缺血模型并分为对照组、匹伐他汀低剂量组及高剂量组。镉还原Griess法、生化检测法测定3组实验结束后血清一氧化氮代谢产物及肝肾功能等含量。激光多普勒血流仪测定3组投药前及术后双下肢血流。蛋白印迹杂交法检测各组双下肢血管内皮生长因子(VEGF)蛋白表达。结果低剂量组实验结束后肝肾功能无明显变化,一氧化氮代谢产物明显高于另外2组,术后缺血肢血流恢复明显,缺血肢VEGF蛋白表达增强。高剂量组肾功能损伤明显高于对照组和低剂量组,一氧化氮代谢产物明显低于低剂量组,术后缺血肢血流恢复不明显,缺血肢VEGF蛋白表达低于低剂量组。结论低剂量匹伐他汀促进了小鼠缺血肢血流的恢复。 Objective: To investigate the effect of different dosages of pitavastatin on the blood flow recovery in the ischemic limbs of mice and thus provide evidences for selecting optimal dosage of pitavastatin in clinical practice, Methods :The mice models of isehemie hind limbs were established and divided into 3 groups: control group, low-dosage pitavastatin group, and high-dosage pitavastatin group, The blood flow of hind limbs both before administration of pitavastatin and after ischemia was measured by laser Doppler flowmetry. The serum levels of the metabolites of nitric oxide (NO) and the liver and kidney functions were determined by Gfiess technique and biochemical technique, respectively. The expression of vascular endothelial growth factor (VEGF) was detected by Western blotting. Results: Compared with control group and high-dosage pitavastatin group, the liver and kidney functions did not change obviously, the NOx level was significantly higher, the blood flow recovered obviously, and the expression of VEGF increased in the low-dosage pitavastatin group, Conclusion:Low-dosage provastatin promotes the blood flow recovery of the ischemic limbs in mice.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2006年第3期251-252,255,共3页 Journal of China Medical University
基金 辽宁省教育厅高等学校科研基金资助项目(05L505)
关键词 匹伐他汀 血流 血管内皮生长因子 一氧化氮 pitavastatin blood flow vascular endothelial growth factor nitric oxide
  • 相关文献

参考文献7

  • 1SATA M,NISHIMATSU H,SUZUKI E,et al.Endothelial nitric oxide synthase is essential for the HMG-CoA reductase Inhibitor cerivastatin to promote collateral growth in response to ischemia[J].FASEB J,2001,15 (13):2530-2532.
  • 2SAITO Y,YAMADA N,TERAMOTO T,et al.Clinical efficacy of pitavastatin,a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,in patients with hyperlipidemia.Dose-finding study using the double-blind,three-group parallel comparison[J].Arzneimittelforschung,2002,52 (4):251-255.
  • 3POURATI I,KIMMELSTIEL C,RAND W,et al.Statin use is associated with enhanced collateralization of severely diseased coronary arteries[J].Am Heart J,2004,148(5):21 -23.
  • 4SUZUKI H,YAMAZAKI H,AOKI T,et al.Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase lnhibitor in guinea pigs[J].Arzneimittelforschung,2001,51(1):38 -45.
  • 5SATA M,NISHIMATSU H,OSUGA J,et al.Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis[J].Hypertension,2004,43 (6):1214 -1420.
  • 6佘强,胡大一.辛伐他汀对心肌梗死大鼠缺血心肌毛细血管新生的影响[J].中国新药与临床杂志,2004,23(6):328-331. 被引量:11
  • 7虞美珍,李强.冠心病患者辛伐他汀治疗前后一氧化氮及一氧化氮和酶的变化观察[J].岭南心血管病杂志,2003,9(6):398-399. 被引量:3

二级参考文献11

  • 1[1]Alexander RW, Dzau VJ. Vascular biology: the past 50 years. Circulation, 2000,102: Ⅳ 112 ~Ⅳ 116
  • 2[2]Heart protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebocontrolled trial. Lancet, 2002,360: 7 ~ 22
  • 3[3]Peterson TR, Jahnsen KE, Vatn S, et al. Benefits of early lipid-lowering intervention in high-risk patients. Clin ther 2000,22(8) :949 ~ 960
  • 4[4]Kardami E, Padue RR, Pasumarthi KBS, et al. Expression,localization and effects of basic fibroblast growth factor on cardiac myocytes. In:kardami E. Growth factors and the cardiovascular system[M].Winnepeg:P. Cummins. Kluwer Academic Publishers, 1993,55 ~ 76
  • 5[5]Laufs U, Lafata VL, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhiditors [ J ]. Circulation, 1998,97:129 ~ 135
  • 6VASA M, FICHTLSCHERER S, ADLER K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease [J]. Circulation, 2001, 103(24): 2885-2890.
  • 7KUREISHI Y, LUO Z, SHIOJIMA I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals [J]. Nat Med, 2000, 6(9): 1004-1010.
  • 8HEESCHEN C, HAMM CW, LAUFS U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes [J]. Circulation, 2002 26, 105(12): 1446-1452.
  • 9WANG Y, GUO Y, ZHANG SX, et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte[J]. J Mol Cell Cardiol, 2002, 34(1): 5-15.
  • 10MORALES-RUIZ M, FULTON D, SOWA G, et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endolial cells is regulated via the serine/threonine kinase Akt[J]. Circ Res, 2000, 86(8):892-896.

共引文献12

同被引文献62

  • 1何玉红,须媚.降血脂药 匹伐他汀(pitavastatin)[J].世界临床药物,2005,26(3):187-187. 被引量:3
  • 2何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 3张月兰,田文,张子新,曾定尹,齐国先.匹伐他汀对Klotho基因敲除杂合子小鼠血管新生的促进作用[J].中国应用生理学杂志,2006,22(2):163-167. 被引量:3
  • 4BOLEGO C, POLI A, CIGNARELLA A, et al. Novel statins: Pharmacological and clinical results [ J ]. Cardiovasc Drugs Ther, 2002,16(3) : 251 -257.
  • 5SUZUKI M, IWASAKI H, FUJIKAWA Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[ J]. Bioarg Med Chem,2001,9 (10) : 2727 -2743.
  • 6SATA M, NISHIMATSU H, SLZUKI E, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia [J]. FASEB J, 2001, 15(13):2530-2532.
  • 7POURATI I, KIMMELSTIEL C, RAND W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries[ J ]. Am Heart J, 2004, 148 (5) : 21 - 23.
  • 8TOKORO T, WANG J, KITAJIMA I, et al. The novel HMG- CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)[J]. Yakugaku Zasshi, 2004,124(3) :121 -126.
  • 9WANG JY, TOKORO T, HIGA S,et al. Anti-inflammatory effect of ptavastatin on NF-KB activated by TNF-a in hepatocellular carcinoma Ceils [ J ]. Biol Pharm Bull ,2006,29 ( 4 ) :634 - 639.
  • 10KAJINAMI K, TAKEKOSHI N, SAITO Y. Pitavastatin: efficacy and safety profites of a novel synthetic HMG-CoA reductase inhibitor[J]. CardiovascDrugRev, 2003,21(3):199-215.

引证文献2

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部